Anti-Retroviral Agents

DRUG4 trials

Sponsors

Shanghai Public Health Clinical Center, CORPORACION DE LUCHA CONTRA EL SIDA, Center for Pharmaceutical Research and Development, Havana, Cuba, National Center of Bioproducts (BIOCEN)

Conditions

HIV-1-infectionHuman Immunodeficiency VirusHuman Immunodeficiency VirusesPatients seropositive to Human Immunodeficiency Virus (HIV). Human Immunodeficiency Virus

Phase 1

Bioequivalence of Abacavir

Active, not recruitingRPCEC00000252

Center for Pharmaceutical Research and Development, Havana, CubaPatients seropositive to Human Immunodeficiency Virus (HIV). Human Immunodeficiency Virus

Start: 2018-03-01Target: 30Updated: 2026-09-14

Phase 3

Evaluation of Biomodulin T® in patients with HIV/AIDS. Phase II/III.

RecruitingRPCEC00000288

National Center of Bioproducts (BIOCEN)Human Immunodeficiency Virus

Start: 2019-06-24Target: 198Updated: 2026-09-14

Phase 4

EFFECTIVENESS AND SAFETY IN GENERIC ABACAVIR/LAMIVUDINE AND EFAVIRENZ IN HIV NAIVE PATIENTS

Active, not recruitingRPCEC00000202

CORPORACION DE LUCHA CONTRA EL SIDAHuman Immunodeficiency Viruses

Start: 2011-01-26Target: 40Updated: 2026-09-14

Unknown Phase

Gut Microbiota and Immune Recovery

Shanghai Public Health Clinical CenterHIV-1-infection

Start: 2017-12-01End: 2019-05-30Target: 80Updated: 2018-03-27

Related Papers

Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011–2012

BMC Infectious Diseases2016-10-037 citations